Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ERK Mutation”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)WithdrawnNCT05279859
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Erasca, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT05221320
What this trial is testing

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Who this might be right for
Tumor, SolidGastrointestinal Cancer
BioMed Valley Discoveries, Inc 47
Testing effectiveness (Phase 2)Ended earlyNCT04534283
What this trial is testing

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Who this might be right for
CancerCancer MetastaticBRAF V600E+4 more
Anita Turk 16
Early research (Phase 1)Ended earlyNCT04249843
What this trial is testing

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Who this might be right for
Solid TumorB-Raf Mutation-Related Tumors
MapKure, LLC 109
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT01709292
What this trial is testing

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Who this might be right for
Thyroid Cancer
M.D. Anderson Cancer Center 24
Testing effectiveness (Phase 2)WithdrawnNCT03109301
What this trial is testing

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Who this might be right for
Neoplasms, Nerve TissueNeurofibromatosis 1Heredodegenerative Disorders, Nervous System+1 more
National Cancer Institute (NCI)
Early research (Phase 1)Active Not RecruitingNCT06104488
What this trial is testing

Avutometinib for People With Solid Tumor Cancers

Who this might be right for
Refractory CancerCNS TumorsCNS Tumor, Adult+12 more
Memorial Sloan Kettering Cancer Center 3
Testing effectiveness (Phase 2)Ended earlyNCT04488003
What this trial is testing

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Who this might be right for
Advanced Solid TumorBRAF Gene MutationBRAF Gene Alteration+6 more
BioMed Valley Discoveries, Inc 104
Not applicableLooking for participantsNCT04395495
What this trial is testing

RASopathy Biorepository

Who this might be right for
RAS MutationNeurofibromatosis 1Noonan Syndrome+11 more
Children's Hospital Medical Center, Cincinnati 1,000
Early research (Phase 1)Temporarily pausedNCT04418167
What this trial is testing

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Solid Tumors
JS InnoPharm, LLC 71
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Not applicableAvailableNCT04566393
What this trial is testing

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Who this might be right for
Pancreatic CancerSmall Bowel CancerColorectal Cancer+18 more
xCures
Early research (Phase 1)Looking for participantsNCT06961565
What this trial is testing

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Who this might be right for
NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more
Pasithea Therapeutics Corp. 56
Testing effectiveness (Phase 2)Ended earlyNCT04985604
What this trial is testing

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorCRAF Gene Amplification+20 more
Day One Biopharmaceuticals, Inc. 23
Large-scale testing (Phase 3)Active Not RecruitingNCT01933932
What this trial is testing

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Who this might be right for
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AstraZeneca 510
Early research (Phase 1)Looking for participantsNCT06962254
What this trial is testing

Imatinib and Trametinib for KRAS-mutated Solid Tumor

Who this might be right for
Solid Tumor Cancer
China Medical University Hospital 10
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Testing effectiveness (Phase 2)Study completedNCT05039177
What this trial is testing

ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Who this might be right for
Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma
Erasca, Inc. 101
Next Page